MedPath

Itacitinib

Generic Name
Itacitinib
Drug Type
Small Molecule
Chemical Formula
C26H23F4N9O
CAS Number
1334298-90-6
Unique Ingredient Identifier
19J3781LPM
Background

Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.

Clinical Trials
Related News

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Phase 1
Completed
Conditions
Graft-versus-host Disease (GVHD)
Interventions
First Posted Date
2015-11-25
Last Posted Date
2019-03-08
Lead Sponsor
Incyte Corporation
Target Recruit Count
31
Registration Number
NCT02614612

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

Phase 1
Terminated
Conditions
Solid Tumors
Interventions
First Posted Date
2015-09-24
Last Posted Date
2019-09-25
Lead Sponsor
Incyte Corporation
Target Recruit Count
142
Registration Number
NCT02559492

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Phase 2
Terminated
Conditions
Refractory Hodgkin Lymphoma
Recurrent Adult Hodgkin's Lymphoma
Interventions
Drug: INCB040093 Monotherapy
First Posted Date
2015-05-28
Last Posted Date
2018-01-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
8
Registration Number
NCT02456675

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Phase 2
Withdrawn
Conditions
Solid Tumors and Hematologic Malignancy
NSCLC (Non-small Cell Lung Carcinoma)
Interventions
Drug: placebo
First Posted Date
2015-02-04
Last Posted Date
2019-03-08
Lead Sponsor
Incyte Corporation
Registration Number
NCT02355431

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

First Posted Date
2014-10-16
Last Posted Date
2020-04-17
Lead Sponsor
Incyte Corporation
Target Recruit Count
83
Registration Number
NCT02265510
Locations
🇺🇸

Site 2, Nashville, Tennessee, United States

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Phase 2
Terminated
Conditions
NSCLC (Non-small Cell Lung Carcinoma)
Interventions
First Posted Date
2014-10-06
Last Posted Date
2018-01-25
Lead Sponsor
Incyte Corporation
Target Recruit Count
9
Registration Number
NCT02257619

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

First Posted Date
2013-12-23
Last Posted Date
2023-09-28
Lead Sponsor
Incyte Corporation
Target Recruit Count
88
Registration Number
NCT02018861
Locations
🇺🇸

Greenville Health System Cancer Institute, Greenville, South Carolina, United States

🇺🇸

Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States

🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

and more 4 locations

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Phase 1
Active, not recruiting
Conditions
B-cell Malignancies
Interventions
First Posted Date
2013-07-23
Last Posted Date
2025-02-13
Lead Sponsor
Incyte Corporation
Target Recruit Count
121
Registration Number
NCT01905813

Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Pancreatic Cancer
Solid Tumors
Interventions
First Posted Date
2013-05-21
Last Posted Date
2019-07-18
Lead Sponsor
Incyte Corporation
Target Recruit Count
55
Registration Number
NCT01858883

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

Phase 2
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Placebo
First Posted Date
2012-07-06
Last Posted Date
2019-03-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
50
Registration Number
NCT01634087
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy